2-Year Clinical Outcomes of an Abluminal Groove–Filled Biodegradable-Polymer Sirolimus-Eluting Stent Compared With a Durable-Polymer Everolimus-Eluting Stent

Xu B, Saito Y, Baumbach A, Kelbæk H, van Royen N, Zheng M, Morel MA, Knaapen P, Slagboom T, Johnson TW, Vlachojannis G, Arkenbout KE, Holmvang L, Janssens L, Ochala A, Brugaletta S, Naber CK, Anderson R, Rittger H, Berti S, Barbato E, Toth GG, Maillard L, Valina C, Buszman P, Thiele H, Schächinger V, Lansky A, Wijns W (2019)

Publication Type: Journal article

Publication year: 2019

Journal

Book Volume: 12

Pages Range: 1679-1687

Journal Issue: 17

DOI: 10.1016/j.jcin.2019.05.001

Abstract

Objectives: The aim of this study was to assess the 2-year clinical outcomes of the Firehawk stent (Shanghai MicroPort Medical Group, Shanghai, China), a novel abluminal groove–filled biodegradable-polymer sirolimus-eluting coronary stent, compared with XIENCE (Abbott Vascular, Santa Clara, California), a durable-polymer everolimus-eluting coronary stent. Background: The long-term outcomes of the Firehawk stent have not been evaluated beyond 1 year in a randomized all-comers clinical trial. Methods: The TARGET All Comers study is a prospective, multicenter, all-comers, randomized, noninferiority trial conducted in Europe. A total of 1,653 patients were randomly assigned to undergo implantation of either the Firehawk or the XIENCE stent. The primary endpoint was target lesion failure, a composite of cardiac death, target vessel myocardial infarction, or ischemia-driven target lesion revascularization. Results: At 2-year follow-up, the incidence of target lesion failure was 8.7% in the Firehawk group versus 8.6% in the XIENCE group (p = 0.92). The event rates of individual components of the primary endpoint were comparable for the 2 groups. Landmark analyses between 1- and 2-year follow-up revealed no statistically significant difference of TLF for the Firehawk versus the XIENCE stent. Beyond 1 year, very late definite or probable stent thrombosis occurred in 3 patients (0.4%) in the Firehawk group and in 7 patients (0.9%) in the XIENCE group (p = 0.34). Conclusions: The 2-year follow-up of the TARGET All Comers study confirms comparable safety and efficacy profiles of the Firehawk and XIENCE stents.

Authors with CRIS profile

Involved external institutions

NHS foundation trust United Kingdom (GB) Klinikum Fulda Germany (DE) Yale University United States (USA) (US) Clinique Axium France (FR) Medical University of Silesia in Katowice / Śląski Uniwersytet Medyczny w Katowicach (SUM) Poland (PL) Hospital Clínic de Barcelona Spain (ES) Imelda vzw Belgium (BE) Universitäts-Herzzentrum Freiburg - Bad Krozingen GmbH Germany (DE) Medizinische Universität Graz Austria (AT) Universitätsklinikum Leipzig Germany (DE) National University of Ireland (NUI), Galway Ireland (IE) Onze-Lieve-Vrouwziekenhuis (OLV Ziekenhuis, OLVZ) Belgium (BE) American Heart of Poland Poland (PL) University Hospital of Wales (UHW) United Kingdom (GB) Cardialysis Netherlands (NL) Zealand University Hospital Denmark (DK) MicroPort Scientific Corporation China (CN) Elisabeth-Krankenhaus Essen Germany (DE) University Medical Centre Utrecht (UMC Utrecht) Netherlands (NL) Tergooi Netherlands (NL) Amsterdam University Medical Centers (Amsterdam UMC) / Amsterdam Universitair Medische Centra Netherlands (NL) Rigshospitalet Denmark (DK) Fuwai Cardiovascular Hospital China (CN)

How to cite

APA:

Xu, B., Saito, Y., Baumbach, A., Kelbæk, H., van Royen, N., Zheng, M.,... Wijns, W. (2019). 2-Year Clinical Outcomes of an Abluminal Groove–Filled Biodegradable-Polymer Sirolimus-Eluting Stent Compared With a Durable-Polymer Everolimus-Eluting Stent. Jacc-Cardiovascular Interventions, 12(17), 1679-1687. https://doi.org/10.1016/j.jcin.2019.05.001

MLA:

Xu, Bo, et al. "2-Year Clinical Outcomes of an Abluminal Groove–Filled Biodegradable-Polymer Sirolimus-Eluting Stent Compared With a Durable-Polymer Everolimus-Eluting Stent." Jacc-Cardiovascular Interventions 12.17 (2019): 1679-1687.

BibTeX: Download